LongBio Pharma says China NMPA accepts LP-003 BLA for seasonal allergic rhinitis

PUBT · 1d ago
LongBio Pharma says China NMPA accepts LP-003 BLA for seasonal allergic rhinitis
  • China’s NMPA accepted LongBio Pharma’s BLA for LP-003 to treat seasonal allergic rhinitis.
  • LP-003 is a next-generation anti-IgE monoclonal antibody; it is LongBio’s first independently developed drug to reach BLA submission.
  • Altruist Biologics supported CMC development, GMP manufacturing, scale-up, and the regulatory filing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longbio Pharma (Suzhou) Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN45907) on September 14, 2026, and is solely responsible for the information contained therein.